DongKook Life Science
Financials
Valuation Metrics
DongKook Life Science's Market Cap is ₩673B. At end of 2025 it was ₩1171B. Ranked #1491 of 2,410 in KR market (top 62%), #859 of 1,631 on KOSDAQ (top 53%), #164 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 71%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 67.33B KRW | KR#1,491/2,410 Sec#164/231 |
| Revenue | 117.75B KRW | KR#1,326/2,410 Sec#83/231 |
| Net Income | 4.97B KRW | KR#1,214/2,410 Sec#82/231 |
| Total Assets | 217.57B KRW | KR#1,251/2,410 Sec#92/231 |
| Net Assets | 132.70B KRW | KR#1,209/2,410 Sec#90/231 |
| Employees | 211 | KR#1,060/2,410 Sec#88/231 |
| Value | ||
| P/E | 13.53x | KR#1,046/2,410 Sec#62/231 |
| P/B | 0.51x | KR#904/2,410 Sec#48/231 |
| PEG | 0.05x | KR#321/2,410 Sec#17/231 |
| P/S | 0.57x | KR#1,066/2,410 Sec#52/231 |
| EV/EBITDA | 9.80x | KR#654/2,410 Sec#30/231 |
| FCF Yield | -7.81% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | 3.75% | KR#1,258/2,410 Sec#86/231 |
| ROA | 2.29% | KR#1,166/2,410 Sec#86/231 |
| Op. Margin | 8.65% | KR#610/2,410 Sec#51/231 |
| Revenue Growth | -1.12% | KR#1,577/2,410 Sec#157/231 |
| Earnings Growth | 285.71% | KR#175/2,410 Sec#9/231 |
| Financial Health | ||
| Debt Ratio | 63.95% | KR#1,144/2,410 Sec#135/231 |
| Total Debt | 37.79B KRW | KR#1,122/2,410 Sec#79/231 |
| FCF | -5.26B KRW | KR#1,504/2,410 Sec#119/231 |
| Cash | 5.20B KRW | KR#1,983/2,410 Sec#184/231 |
| Current Ratio | 1.73x | KR#1,013/2,410 Sec#113/231 |
| Net Debt/EBITDA | 3.20x | KR#920/2,410 Sec#68/231 |
| Performance | ||
| 1Y Return | -44.09% | KR#1,815/2,410 Sec#159/231 |
| 1M Return | -24.96% | KR#2,168/2,410 Sec#214/231 |
| From 52W High | -48.78% | KR#1,083/2,410 Sec#82/231 |
| 1Y MDD | -47.63% | KR#848/2,410 Sec#69/231 |
| Trading | ||
| Volume | 198,066 shares | KR#416/2,410 Sec#46/231 |
| Trading Value | 415.3M KRW | KR#940/2,410 Sec#104/231 |
| Foreign Own. | 2.40% | KR#1,481/2,410 Sec#141/231 |
| Per Share | ||
| EPS | 156 KRW | KR#1,349/2,410 Sec#89/231 |
| BPS | 4,149 KRW | KR#1,651/2,410 Sec#121/231 |
Company Info
Dongguk Pharmaceutical Life Science, established in 2017 and listed on KOSDAQ in 2025, manufactures and sells contrast agents, and distributes medical devices and diagnostic equipment. As a specialized contrast agent company, it launched Korea's first First generic contrast agent, Pamiray, and has 17 partners in 25 countries. Leveraging its radiology expertise and sales network from its contrast agent business, the company is expanding its AI medical device business and providing Total Patient Care. It is headquartered in Gangnam-gu, Seoul.